DoD Breast Cancer, Breakthrough Award Levels 1 and 2 | W81XWH 21 BCRP BTA12 2

Opportunity Information: Apply for W81XWH 21 BCRP BTA12 2

The DoD Breast Cancer Research Program (BCRP) Breakthrough Award Levels 1 and 2 (Funding Opportunity Number W81XWH-21-BCRP-BTA12-2) is designed to fund breast cancer research that has a real chance of changing the field rather than adding another incremental step. The core expectation is impact: proposed work should plausibly accelerate progress toward ending breast cancer by opening a genuinely new and better direction for prevention, detection, or treatment compared with what is already approved or currently being tested clinically. Applicants are expected to be explicit about who benefits from the work, meaning they should clearly identify the specific breast cancer patient populations or at-risk groups that the research is intended to help and explain the path from the research outcomes to those people.

This mechanism is part of a larger Breakthrough Award structure that includes four funding levels, each tied to a different stage on the path to clinical application. The key point is that applicants must choose the level that matches the maturity and intent of the project, and that choice is judged based on the defined scope for that level rather than the size of the requested budget. Levels 3 and 4 exist under separate program announcements, while this announcement focuses only on Levels 1 and 2. The program stresses that a strong project placed into the wrong level will not be recommended for funding even if it would have fit well under a different level, so aligning the project with the correct level is treated as a gating issue, not a minor administrative detail.

Funding Level 1 is geared toward bold, early-stage ideas that are high-risk/high-reward. This is the space for brand-new concepts, untested theories, or emerging approaches aimed at an important breast cancer problem where the main goal is to establish proof of concept. To encourage creativity and the exploration of new research avenues, Level 1 does not require preliminary data. In practice, that means reviewers are looking for a compelling scientific rationale, a clear and testable concept, and an experimental plan strong enough to convincingly demonstrate whether the idea works, even if the idea has not yet been validated in prior studies.

Funding Level 2 is positioned for projects that have moved past the earliest stage and are already backed by substantial preliminary findings or published data. The emphasis here is on strengthening and validating a pathway toward clinical translation within a clearly defined breast cancer context. In other words, Level 2 expects that the scientific foundation is already established and the proposal can credibly argue not just that the biology is interesting, but that it is ready to be advanced toward real-world use, whether that means translation into clinical tools, interventions, or clinically meaningful decision-making. Within Level 2, the announcement also highlights population science and prevention studies. These projects must still be supported by substantial data and must validate clinical translation in a well-defined context, but the program acknowledges that these studies can demand more resources due to the complexity of human subjects research and the use of human biospecimens. With strong justification, these population science and prevention efforts may request a higher funding amount and an additional year of performance compared to typical Level 2 projects.

A notable feature of the opportunity is the Partnering PI Option, which is meant to promote real, balanced scientific collaborations rather than superficial co-investigator arrangements. Under this option, the application includes two principal investigators: an Initiating PI who handles most submission and administrative responsibilities, and a Partnering PI who shares major responsibility for the science. The expectation is that both PIs contribute substantially and comparably to the intellectual design of the project and to execution, including co-developing the Project Narrative and Statement of Work. The program expects funding to be distributed in a balanced way between the two PIs unless there is a clear reason it should not be, and it wants the application to directly explain why doing the work together is essential and why the partnership is stronger than two separate efforts. New collaborations are encouraged but not mandatory.

At the same time, the announcement is careful about what does not qualify as a true partnering arrangement. It discourages naming a person as Partnering PI on multiple Level 1 and 2 submissions unless the projects clearly tackle distinct research questions, which is intended to prevent token or overextended partnerships. It also states that mentor-trainee pairings (for example, a mentor and their current postdoc or junior investigator) do not meet the intent of the option. Similarly, arrangements where one PI mainly supplies materials (such as samples, animal models, or investigational agents) while the other PI conducts most experiments and analyses are not aligned with what the program means by a genuine collaboration. If funded, each PI is named on an individual award within the recipient organization, reinforcing that both roles are treated as substantial and accountable.

Finally, beyond the PI structure, the opportunity emphasizes staffing and capability. Applications are expected to include a robust team with the combined expertise needed to carry out the work successfully, particularly breast cancer-relevant knowledge and the technical backgrounds required by the proposed approach. Administrative details from the source listing include that the sponsoring agency is the Department of Defense, Department of the Army (USAMRAA), the opportunity is listed under CFDA 12.420, and it uses grant and cooperative agreement instruments. Eligibility is described as unrestricted (open to any entity type, subject to any additional eligibility language in the full announcement). The listing indicates an anticipated total of about 15 awards, and while an award ceiling is not specified in the provided summary data, the practical constraint is the funding-level scope and justification, especially for Level 2 population science and prevention studies that may warrant additional time and resources.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Breast Cancer, Breakthrough Award Levels 1 and 2" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 26, 2021.
• Applicants must submit their applications by Sep 14, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 15 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 BCRP BTA12 2

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: